The gap between effect of drugs and effectiveness of treatments

Journal of the Neurological Sciences

Volumn 259, Issue 1-2, 2007, Pages 128-132

  Sorensen, Per Soelberg ^a  

^a Mental Health Center Glostrup   (Denmark)

Author keywords

Effectiveness; Immune system; Immunomodulation; Immunosuppression; Multiple sclerosis; Therapies; Treatment

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; GLATIRAMER; NATALIZUMAB;

ARTICLE; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATION; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE;

BIOLOGICAL RESPONSE MODIFIERS; DISABILITY EVALUATION; HUMANS; INTERFERON-BETA; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34447102777     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.10.024     Document Type: Article

References (25)

1. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352 9139 (Nov 7 1998) 1491-1497
2. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39 3 (1996) 285-294
3. Panitch H., Miller A., Paty D., and Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63 10 (Nov 23 2004) 1788-17895
4. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 9139 (Nov 7 1998) 1498-1504
5. SPECTRIMS. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 56 11 (Jun 12 2001) 1496-1504
6. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 4 (1993) 655-661
7. Uhm J.H., Dooley N.P., Stuve O., Francis G.S., Duquette P., Antel J.P., et al. Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon beta-1b therapy. Ann Neurol 46 3 (Sep 1999) 319-324
8. Liu Z., Pelfrey C.M., Cotleur A., Lee J.C., and Rudick R.A. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol 112 1-2 (Jan 1 2001) 153-162
9. Farina C., Weber M.S., Meinl E., Wekerle H., and Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 4 9 (Sep 2005) 567-575
10. Neuhaus O., Farina C., Wekerle H., and Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56 6 (Mar 27 2001) 702-708
11. Fridkis-Hareli M., Neveu J.M., Robinson R.A., Lane W.S., Gauthier L., Wucherpfennig K.W., et al. Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. J Immunol 162 8 (Apr 15 1999) 4697-4704
12. 2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 105 7 (Apr 2000) 967-976
13. Ziemssen T., Kumpfel T., Klinkert W.E., Neuhaus O., and Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 125 Pt 11 (Nov 2002) 2381-2391
14. Comi G., Filippi M., and Wolinsky J.S. European/Canadian multicenter, double-blind, randomized, placebo- controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49 3 (Mar 2001) 290-297
15. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group [see comments]. Neurology 45 (1995) 1268-1276
16. Wolinsky J.S., Narayana P.A., O'Connor P., Coyle P.K., Ford C., Johnson K., Miller A., Pardo L., Kadosh S., and Ladkani D. PROMiSe Trial Study Group. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 61 1 (Jan 2007) 14-24
17. Moreau T., Coles A., Wing M., Thorpe J., Miller D., Moseley I., et al. CAMPATH-IH in multiple sclerosis. Mult Scler 1 6 (Jul 1996) 357-365
18. Coles A.J., Wing M.G., Molyneux P., Paolillo A., Davie C.M., Hale G., et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46 3 (Sep 1999) 296-304
19. Coles A.J., Cox A., Le P.E., Jones J., Trip S.A., Deans J., et al. The window of therapeutic opportunity in multiple sclerosis. Evidence from monoclonal antibody therapy. J Neurol 253 1 (Jan 2006) 98-108
20. Filippi M., Rovaris M., Iannucci G., Mennea S., Sormani M.P., and Comi G. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 55 11 (Dec 12 2000) 1714-1718
21. Rice G.P., Filippi M., and Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 54 5 (Mar 14 2000) 1145-1155
22. Rice G.P., Hartung H.P., and Calabresi P.A. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64 8 (Apr 26 2005) 1336-1342
23. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 9 (Mar 2 2006) 899-910
24. Rudick R.A., Stuart W.H., Calabresi P.A., Confavreux C., Galetta S.L., Radue E.W., et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354 9 (Mar 2 2006) 911-923
25. Kutzelnigg A., Lucchinetti C.F., Stadelmann C., Bruck W., Rauschka H., Bergmann M., et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128 Pt 11 (Nov 2005) 2705-2712